Neuvivo and the U.S. Food and Drug Administration (FDA) have agreed on a regulatory pathway toward the potential approval of ...

In ALS, the loss of certain proteins turns off a gene called UNC13A that needs to stay active for nerve cell communication, a ...

Completing a project in her backyard was satisfying for columnist Kristin Neva, whose work as an ALS caregiver is repetitive and ongoing.

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Columnist Dagmar Munn feels as if she's finding her voice again as she picks up her speech exercises, and then some.

Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other ...

The ongoing EAP that is providing ALS patients with access to MN-166 (ibudilast) outside of a clinical trial is adding more ...

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

AUT00201, an oral small molecule, reduced the loss of motor neurons and eased motor symptoms in a mouse model of ALS, a study ...

CB03-154 is a newer ALS therapy that's designed to open nerve cells' KCNQ2 and KCNQ3 potassium channels without affecting ...

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the treatment of ALS.